OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
August 12, 2020
The company will use the acquisition to further its drug development pipeline in women’s healthcare.
August 10, 2020
Citing undisclosed allegations against Kodak, the DFC placed a hold on a potential $765 million loan to launch US-based API manufacturing.
August 06, 2020
The companies have entered into an exclusive licensing agreement to develop, manufacture, and commercialize efinopegdutide, an investigational drug for treating nonalcoholic steatohepatitis.
August 04, 2020
PPD announced it will provide drug development services to advance Pfizer’s portfolio.
August 03, 2020
The COVID-19 pandemic has raised several questions about the safety of the pharmaceutical materials supply chain. Is onshoring the answer?
Particle engineering is a useful tool to manipulate API particles into a form that is manufacturable and deliverable to the patient.
Understanding and overcoming excipient variation are crucial for successful continuous processes.
August 02, 2020
Time sure flies, except when you are waiting for something to happen.
The right outsourcing partner should open up access to expertise and technical capabilities in a broad range of dosage forms to ensure commercial success.
July 21, 2020
Catalent has unveiled plans to invest in a European center of excellence for clinical biologics formulation development and drug product fill/finish services at its facility in Limoges, France.